medicalxpress - Children with peanut allergies may not need large doses of peanut oral immunotherapy (OIT) to build protection against peanuts, finds a new study led by The Hospital for Sick Children (SickKids) and Montreal Children's Hospital.
AI Summary: Emerging study results indicate that administering lower doses of peanut oral immunotherapy can build effective resistance in children with peanut allergies while minimizing adverse side effects. This finding could lead to safer, more accessible treatment protocols that transform current clinical practices and improve overall patient outcomes for pediatric allergy management.
Bacterial Traces in Brain Tumors May Influence Their Behavior / 6 months
Therapeutic HPV vaccine slows throat tumors in preclinical tests / 3 months
Gene‑editing trials explore one‑time fix for high cholesterol / 3 months
Bayer’s Asundexian Reduces Stroke Risk by 26% in Phase 3 Trial / 3 months
Eikon Therapeutics raises $381M IPO for cancer drug advancement / 3 months
Aktis Oncology IPO boosts radiopharmaceutical pipeline / 4 months
Tumor bacteria drive head and neck immunotherapy resistance / 4 months
StackHealth RSS

StackHealth Time Machine
NorthFeed Inc. Terms and Conditions / Privacy Policy
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.